Nexalin Technology, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company at a crossroads where high-potential clinical catalysts clash with an acute liquidity crisis. On one hand, the transition of the HALO device into production for clinical trials and the FDA's engagement on the SYNC system provide a clear path toward value creation. The surge in gross margins suggests that the underlying technology is commercially viable when licensed, providing a glimpse of the company's potential future state. However, the immediate outlook is dominated by survival risks. The combination of a 'going concern' warning, material weaknesses in financial reporting, and a ticking clock on Nasdaq compliance creates a high-volatility environment for investors. The outcome for Nexalin will likely be decided by its ability to either secure a significant new capital infusion or produce early clinical data that triggers a sharp recovery in the share price before the July deadline.